IBT Reference Laboratory Appoints Dr. F. John Mills to its Board of Directors.
ProGene Biomedical, Inc. (d/b/a IBT Reference Laboratory), a national clinical and pharmaceutical services laboratory, announced that Dr. F. John Mills has joined its Board of Directors.
Lenexa, KS, June 2, 2005. ProGene Biomedical, Inc. (d/b/a IBT Reference Laboratory), a national clinical and pharmaceutical services laboratory, announced that Dr. F. John Mills has joined its Board of Directors. "Dr. Mills brings over 20 years of senior executive experience in drug discovery and the pharmaceutical services industry to our Board. His unique background will be invaluable as IBT seeks to build a premier company in the specialty pharmaceutical services sector," according to John F. Halsey, PhD, the President and Chief Executive Officer of ProGene Biomedical, Inc.
Dr. Mills, who received both medical and doctoral degrees in the United Kingdom, was an executive at Janssen Pharmaceutical from 1983 to 1991, serving as UK Medical Director and Regional Medical Director for Asia. From 1992 to 2002, Dr. Mills held various senior executive positions with Covance, Inc., including General Manager of European Clinical Services, Global General Manager of Central Laboratory Services and President of Clinical Support Services. Dr. Mills is the co-founder and Chief Executive Officer of BioStorage Technologies, Inc., a leading provider of biological sample repository services to pharmaceutical, biotechnology and other life sciences companies (www.bst-indy.com).
"John knows what it takes to build a well-respected, laboratory services business from his years at Covance," commented David Parker, IBT's Chairman and a partner at Ampersand Ventures. "His input and guidance will be very important as the Company looks to capitalize on growing demand for its assay development and diagnostic testing services from pharmaceutical sponsors to support their clinical trials."
About IBT Reference Laboratory:
Founded in 1983, IBT Reference Lab is a national research and specialty clinical lab that provides a range of esoteric tests in the areas of clinical immunology, allergy and molecular biology. In addition to all of the major national clinical laboratories, the Company provides its unique biomarker and immunotoxicology testing services to pharmaceutical and biotechnology companies and academic institutions (www.ibtreflab.com).
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
